20-21 August 2026
Successful applicants will be contacted during the first week of July 2026 and will receive a link to confirm participation, select accommodation dates, and pay the partially refundable registration fee of EUR 300.
Payment Deadline
To secure participation, the registration fee must be paid within 7 days of receiving the acceptance notification, and no later than 15 July 2026, unless otherwise agreed by the EAP Secretariat.
Places cannot be reserved without completed payment.
Upfront Payment Requirement
A €300 upfront payment is required to confirm your registration and accommodation booking.
Participants who attend the full course will receive a refund on 1 September 2025 as follows:
Travel Bursary recipients will be reimburse separately as soon as possible and by latest 30 September 2026.
No refund will be granted for partial attendance or early departure.
Before 31 July 2026
Full refund (EUR 300, minus transaction fees)
Between 1 August – 31 August 2026
Partial refund of EUR 150
(EUR 150 retained to cover accommodation commitments)
Between 1 September – 30 September 2026
Partial refund of EUR 75
(EUR 225 retained to cover accommodation commitments)
From 1 October 2026 onwards
No refund
(full amount retained)
No-shows
No refund will be granted.
Increasing the positive impact of nutrition.
Transforming the practice of medicine through breakthrough science.
New ways to test high-risk medical devices.
Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.
It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.
